Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced that the company's self-developed PD-1/VEGF/CTLA-4 three-specific antibody CS2009 achieved a major clinical validation milestone, and announced the latest clinical data in the form of two quick oral reports at the 2026 European Society of Medical Oncology (ESMO) conference.

Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced that the company's self-developed PD-1/VEGF/CTLA-4 three-specific antibody CS2009 achieved a major clinical validation milestone, and announced the latest clinical data in the form of two quick oral reports at the 2026 European Society of Medical Oncology (ESMO) conference.